A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma (NCT05529316)

🧪 Interventions in This Study

• Botensilimab (DRUG)
• Balstilimab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (51 Sites)

Showing the first 25 of 51 sites.

• Scottsdale Healthcare Hospitals DBA HonorHealth — Scottsdale, Arizona
• Virginia K. Crosson Cancer Center at St. Jude Medical Center — Fullerton, California
• Providence Saint John's Health Center — Santa Monica, California
• Yale University School of Medicine - Yale Cancer Center — New Haven, Connecticut
• Georgetown University Medical Center — Washington D.C., District of Columbia
• Dana-Farber Cancer Institute — Boston, Massachusetts
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
• Universitair Ziekenhuis Brussel — Jette,
• Oncosite - Centro de Pesquisa Clinica Em Oncologia — Ijuí,
• Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho — Jaú,
• Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa — Porto Alegre,
• INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva — Rio de Janeiro,
• Hospital Sirio Libanes — São Paulo,
• Real e Benemerita Associaçao Portuguesa de Beneficencia - A Beneficencia Portuguesa de Sao Paulo — São Paulo,
• Hospital A.C. Camargo Cancer Center — São Paulo,
• CHU Amiens Picardie - Hopital Sud — Amiens,
• CHU Grenoble-Alpes - Hopital Michallon — La Tronche,
• Centre Leon Berard — Lyon,
• CHU de Nantes — Nantes,
• AP-HP Hopital Saint-Louis — Paris,
• Centre Eugene Marquis — Rennes,
• Gustave Roussy — Villejuif,
• Universitaetsklinikum Essen — Essen,
• Universitaetsklinikum Hamburg-Eppendorf — Hamburg,
• Universitaetsklinikum Heidelberg — Heidelberg,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Melanoma

• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — Fairhope, Alabama
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — Birmingham, Alabama
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — Mobile, Alabama
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — Pittsburgh, Pennsylvania
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors — St Louis, Missouri

Explore by condition: All Advanced Melanoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.